Kenvue Inc. is a prominent American consumer health company that became independent from Johnson & Johnson in 2023. Based in Skillman, New Jersey, with plans to move to Summit, Kenvue is recognized as the largest pure-play consumer health company by revenue. The company manages a diverse portfolio of well-known brands, including Aveeno, Band-Aid, Benadryl, Zyrtec, Johnson’s, Listerine, Neutrogena, and Tylenol, serving around 1.2 billion people worldwide.
Kenvue focuses on consumer health products that meet everyday care needs, emphasizing science-backed solutions endorsed by healthcare professionals. The company operates across three segments and reported net sales of approximately $15.5 billion in 2024, with a significant portion of sales coming from international markets. Kenvue is committed to innovation, introducing new products annually and holding numerous top brand positions in its categories. Its mission is to provide innovative care solutions that promote healthier individuals and a healthier planet.
Kenvue Inc. is a prominent American consumer health company that became independent from Johnson & Johnson in 2023. Based in Skillman, New Jersey, with plans to move to Summit, Kenvue is recognized as the largest pure-play consumer health company by revenue. The company manages a diverse portfolio of well-known brands, including Aveeno, Band-Aid, Benadryl, Zyrtec, Johnson’s, Listerine, Neutrogena, and Tylenol, serving around 1.2 billion people worldwide.
Kenvue focuses on consumer health products that meet everyday care needs, emphasizing science-backed solutions endorsed by healthcare professionals. The company operates across three segments and reported net sales of approximately $15.5 billion in 2024, with a significant portion of sales coming from international markets. Kenvue is committed to innovation, introducing new products annually and holding numerous top brand positions in its categories. Its mission is to provide innovative care solutions that promote healthier individuals and a healthier planet.
